Brits buy Dorland Global in $20M deal

Share this article:
Publicly held Huntsworth PLC, based in London, has purchased Dorland Global Corp., for $20.7 million in cash, extending the reach of its healthcare division into the US market.

The acquisition covers its two units, Dorland Global Health Communications and Dorland Global Public Relations.

The sale price for the previously independent agency will be shared by 10 shareholders, along with co-founders Harry and Rita Sweeney. The deal also may include deferred compensation based on Dorland profits for the year ending Dec. 31, 2007, plus a payment to be made based on three-year profits through 2010, Huntsworth said.

The maximum price was capped at $50 million. Dorland reported 2006 gross profit of $3.5 million and gross assets of $11 million as of year end.
The existing management team will continue to operate the business, reporting to David Rowley, chief executive of Huntsworth Health.

Dorland will serve as a US footprint for the Huntsworth Health division, the largest healthcare firm in the UK.

In an interview with MM&M, Rita Sweeney said being part of a larger agency will help Dorland “take on and pitch and win larger global accounts…that was the whole strategy to begin with.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...